Immunogenicity and Safety of Booster Dose of S-268019-b or Tozinameran in Japanese Participants: An Interim Report of Phase 2/3, Randomized, Observer-Blinded, Noninferiority Study

Masaharu Shinkai, Takuhiro Sonoyama, Akari Kamitani, Risa Shibata, Naomi Seki, Shinya Omoto, Masahiro Shinoda, Takashi Sato, Naoki Ishii, Kenji Igarashi, Mari Ariyasu
doi: https://doi.org/10.1101/2022.03.03.22271827

Article usage

Article usage: March 2022 to April 2025

AbstractFullPdf
Mar 2022221057578
Apr 202254942195
May 202242112133
Jun 20222441477
Jul 2022202336
Aug 2022172751
Sep 20221601322
Oct 2022184124
Nov 2022178552
Dec 202294324
Jan 202376826
Feb 202382529
Mar 202386415
Apr 202394828
May 202375423
Jun 202366414
Jul 202358125
Aug 2023601233
Sep 202367723
Oct 202379828
Nov 2023731318
Dec 202338115
Jan 202446986
Feb 202455318
Mar 202450916
Apr 202467926
May 202450237
Jun 202453121
Jul 202461624
Aug 202449328
Sep 202471514
Oct 202463611
Nov 202439323
Dec 202443318
Jan 202556126
Feb 202556024
Mar 2025581124
Apr 202530324
Back to top
Posted April 01, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Immunogenicity and Safety of Booster Dose of S-268019-b or Tozinameran in Japanese Participants: An Interim Report of Phase 2/3, Randomized, Observer-Blinded, Noninferiority Study
Masaharu Shinkai, Takuhiro Sonoyama, Akari Kamitani, Risa Shibata, Naomi Seki, Shinya Omoto, Masahiro Shinoda, Takashi Sato, Naoki Ishii, Kenji Igarashi, Mari Ariyasu
medRxiv 2022.03.03.22271827; doi: https://doi.org/10.1101/2022.03.03.22271827
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area